Implementation of an Oral Care Protocol for Primary Diabetes Care: A Pilot Cluster-Randomized Controlled Trial

Verhulst, Martijn J. L.; Teeuw, Wijnand J.; Gerdes, Victor E. A.; Loos, Bruno G.

doi:10.1370/afm.2645

Cited by 4 publications

(1 citation statement)

References 35 publications

(40 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Diabetes affects more than 451 million people worldwide and has thus become a major public health issue. 1 One national epidemiological study showed that in China, there were 129.8 million individuals with diabetes and that the overall prevalence of diabetes grew from 9.7% in 2010 to 11.2% in 2017. 2 Ninety per cent of patients with diabetes have type 2 diabetes.…”

Section: Introductionmentioning

confidence: 99%

Cost‐utility analysis of semaglutide for type 2 diabetes after its addition to the National Medical Insurance System in China

et al. 2022

Diabetes Obesity Metabolism

View full text Add to dashboard Cite

Introduction:The main research purpose is to compare the long-term costeffectiveness of semaglutide (SEMA) with that of dulaglutide (DULA) for patients with inadequately controlled type 2 diabetes throughout their lifetime. If necessary, the second aim is to investigate a further price cut for SEMA to provide sound advice for government drug price adjustments. Methods: Cost-utility analysis was performed by the United Kingdom Prospective Diabetes Study Outcomes Model 2 (UKPDS OM2) from the perspective of health care providers in China. Baseline characteristics and clinical efficacy of SEMA and DULA were sourced from the high-dose comparison in the SUSTAIN-7 trial. A binary search was used to identify the scope for further reduction in the price of SEMA. The impact of individual parameters was assessed with sensitivity analyses.Results: Main analysis (SEMA vs. DULA) revealed a mean difference in qualityadjusted life years (QALYs) of 0.04 QALYs and costs of $1132.29. The incremental cost-utility ratio was $26 957.44/QALY, showing that SEMA was a better option compared with DULA. In sensitivity analyses, the discount rate made the greatest contribution to the incremental cost-utility ratio. In the binary search, there was still scope to reduce the SEMA cost further by approximately 6.83% to be cost-effective, taking DULA as a reference. Conclusion:After its addition to the National Medical Insurance System in China, SEMA is expected to be a cost-effective choice compared with DULA for patients with type 2 diabetes with inadequately controlled from the cost-utility analysis. However, there is still scope to reduce the annual cost of SEMA further.

show abstract

Section: Introductionmentioning

confidence: 99%

Cost‐utility analysis of semaglutide for type 2 diabetes after its addition to the National Medical Insurance System in China

et al. 2022

Diabetes Obesity Metabolism

View full text Add to dashboard Cite

show abstract

Effectiveness of oral health promotion interventions for people with type 2 diabetes delivered by non-dental health care professionals: a systematic review

Harada

Prajapati

Poudel

et al. 2022

Global Health Action

View full text Add to dashboard Cite

Current scientific evidence for why periodontitis should be included in diabetes management

Borgnakke

2024

Front. Clin. Diabetes Healthc.

View full text Add to dashboard Cite

This Perspective provides a brief summary of the scientific evidence for the two-way links between periodontal diseases and hyperglycemia (diabetes mellitus [DM] and pre-DM). It delivers in a nutshell current scientific evidence for manifestations of hyperglycemia on periodontal health status and effects of periodontal diseases on blood glucose levels and in turn incidence, progression, and complications of diabetes. Of outmost importance is presentation of scientific evidence for the potential of routine periodontal treatment to lower blood glucose levels, providing a novel, economical tool in DM management. Non-surgical periodontal treatment (“deep cleaning”) can be provided by dental hygienists or dentists in general dental offices, although severe cases should be referred to specialists. Such therapy can decrease the costs of DM care and other health care costs for people with DM. The great importance of a healthy oral cavity free of infection and subsequent inflammation – especially periodontitis that if untreated will cause loosening and eventually loss of affected teeth – has largely gone unnoticed by the medical community as the health care curricula are largely void of content regarding the bi-directional links between oral health and systemic health, despite elevation of blood glucose levels being an integral part of the general systemic inflammation response. The importance of keeping disease-free, natural teeth for proper biting and chewing, smiling, self-esteem, and pain avoidance cannot be overestimated. Medical and dental professionals are strongly encouraged to collaborate in patient-centered care for their mutual patients with – or at risk for – hyperglycemia.

show abstract

Implementation of an Oral Care Protocol for Primary Diabetes Care: A Pilot Cluster-Randomized Controlled Trial

Cited by 4 publications

References 35 publications

Cost‐utility analysis of semaglutide for type 2 diabetes after its addition to the National Medical Insurance System in China

Cost‐utility analysis of semaglutide for type 2 diabetes after its addition to the National Medical Insurance System in China

Effectiveness of oral health promotion interventions for people with type 2 diabetes delivered by non-dental health care professionals: a systematic review

Current scientific evidence for why periodontitis should be included in diabetes management

Contact Info

Product

Resources

About